Tandem Diabetes Care (TNDM) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.10

Estimate

-$0.24

Surprise

+58.4%

Revenue (period 2026-09-30)

$283.7M

Score today

5.4/10

Revenue source: xbrl.

Tandem Diabetes Care (TNDM) reported a narrower loss than forecast — adjusted EPS of -$0.10 against the -$0.24 estimate (a 58.4% beat on a still-unprofitable quarter).

• Barclays Maintains Equal-Weight on Tandem Diabetes Care, Raises Price Target to $20 — benzinga, 2026-11-06
• Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25 — benzinga, 2026-11-06
• Tandem Diabetes Care Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05

TrendMatrix currently rates TNDM Sell at 5.4/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +58.4% surprise compares with a +45.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.73

Price target

$24.99

Stop

$15.55

Upside to target

+49.4%

Reward-to-risk

3.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Devices

Market cap

$1.25B

P/E (fwd)

113.2

52-week range

$12.26–$29.65

Off 52-week high

43.6%

RSI (14)

52

Volume vs avg

0.98×

Score today

5.4/10